KORU Medical Systems, Inc. (KRMD) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended March 31, 2025. KORU Medical Systems, Inc. develops, manufactures, and commercializes large volume subcutaneous infusion solutions, primarily for the delivery of immunoglobulin to treat Primary Immunodeficiency Diseases (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The company operates as a single segment with revenue streams from domestic core, international core, and pharma services/clinical trials.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Revenues | $9,635,075 | $8,197,798 |
| Gross Profit | $6,046,335 | $5,103,298 |
| Gross Margin | 62.8% | 62.3% |
| Net Loss | $(1,166,237) | $(1,935,958) |
| Net Loss Per Share (Basic & Diluted) | $(0.03) | $(0.04) |
| Cash and Cash Equivalents | $8,735,834 | $10,820,317 |
| Net Cash Used in Operating Activities | $(237,467) | $(346,720) |
| Total Debt (Note Payable) | $137,180 | $271,152 |
| Working Capital | $11,199,751 | $11,930,590 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 17.5% year-over-year. This was driven by a 16.4% increase in Domestic Core revenue and a 35.6% increase in International Core revenue.
- Segment Performance: Pharma services and clinical trials revenue declined 38.6% due to lower clinical trial activity, partially offsetting core growth.
- Profitability: Gross margin improved to 62.8% from 62.3%, attributed to favorable product revenue mix. Net loss narrowed by 39.8% to $1.17 million.
- Operating Expenses: Total operating expenses rose 3.2% to $7.29 million. Selling, general, and administrative (SG&A) expenses increased 11.2% due to higher compensation and legal fees, while Research and Development (R&D) expenses decreased 24.5% due to project timing.
- Liquidity: Cash balances decreased by $0.85 million during the quarter, primarily due to operating losses and increased capital expenditures for manufacturing equipment ($0.44 million).
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects current cash on hand ($8.7 million) and operating cash flows to be sufficient to meet requirements for at least the next twelve months. Future capital needs may require drawing on a $5 million revolving credit facility or raising additional equity/debt.
- Tariff Risks: The company faces uncertainty regarding new U.S. tariffs announced in April 2025 (baseline 10% on all countries plus reciprocal tariffs). While management does not currently expect a material impact on revenues or cost of goods, they are evaluating mitigation strategies.
- Regulatory and Market Risks: Risks include FDA compliance, reimbursement changes, dependence on key personnel, and the ability to penetrate new markets. The company maintains a full valuation allowance against net deferred tax assets due to cumulative losses.
- Debt Facilities: The company has a $5 million revolving credit facility and a $5 million term loan facility, both amended in March 2025 to extend maturity dates to late 2026. No borrowings were outstanding under these facilities as of March 31, 2025.
Investor Verification Checklist
- Verify the sustainability of the 35.6% international revenue growth and the impact of distributor stocking levels on future quarters.
- Monitor the impact of the 38.6% decline in pharma services revenue on overall margin stability.
- Assess the potential financial impact of the newly announced U.S. tariffs on the cost of goods sold and gross margin.
- Review the timeline for new product introductions and the associated capital expenditure requirements.
- Confirm the company's ability to maintain liquidity without dilutive equity issuances or debt drawdowns over the next 12 months.